This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Summary

Nimotuzumab is an EGFR-targeting monoclonal antibody used in the treatment of squamous cell carcinomas of the head and neck and glioblastomas.

Generic Name
Nimotuzumab
DrugBank Accession Number
DB06192
Background

Not Available

Type
Biotech
Groups
Investigational
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Protein Structure
Protein Chemical Formula
Not Available
Protein Average Weight
Not Available
Sequences
Not Available
Synonyms
  • Nimotuzumab

Pharmacology

Indication

Investigated for use/treatment in head and neck cancer, brain cancer, pediatric indications, pancreatic cancer, lung cancer, and colorectal cancer.

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbciximabThe risk or severity of adverse effects can be increased when Abciximab is combined with Nimotuzumab.
AdalimumabThe risk or severity of adverse effects can be increased when Adalimumab is combined with Nimotuzumab.
AducanumabThe risk or severity of adverse effects can be increased when Nimotuzumab is combined with Aducanumab.
AlemtuzumabThe risk or severity of adverse effects can be increased when Alemtuzumab is combined with Nimotuzumab.
AlirocumabThe risk or severity of adverse effects can be increased when Nimotuzumab is combined with Alirocumab.
AmivantamabThe risk or severity of adverse effects can be increased when Nimotuzumab is combined with Amivantamab.
AnifrolumabThe risk or severity of adverse effects can be increased when Nimotuzumab is combined with Anifrolumab.
AnsuvimabThe risk or severity of adverse effects can be increased when Nimotuzumab is combined with Ansuvimab.
Anthrax immune globulin humanThe risk or severity of adverse effects can be increased when Nimotuzumab is combined with Anthrax immune globulin human.
Antilymphocyte immunoglobulin (horse)The risk or severity of adverse effects can be increased when Nimotuzumab is combined with Antilymphocyte immunoglobulin (horse).
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
International/Other Brands
DiaCIM / RadioTheraCIM / TheraCIM / Theraloc

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
6NS400BXKH
CAS number
780758-10-3

References

General References
Not Available
Wikipedia
Nimotuzumab

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4Unknown StatusTreatmentNasopharyngeal Carcinoma (NPC)1
4Unknown StatusTreatmentUnresectable Pancreatic Cancer1
3Active Not RecruitingTreatmentSquamous Cell Carcinoma of the Head and Neck (SCCHN)1
3CompletedTreatmentAdults With Glioblastoma Multiforma1
3CompletedTreatmentCervical Cancer1
3CompletedTreatmentCervical Cancer Recurrent or Persistent / Monoclonal Antibody in Cervical Cancer Treatment / Palliative Treatment1
3CompletedTreatmentNasopharyngeal Carcinoma (NPC)1
3RecruitingTreatmentChemoradiotherapy / Chemotherapy Effects / Esophageal Cancer / Esophagogastric Juction Cancer / Immunotherapy / Surgery / Targeted Therapy1
3RecruitingTreatmentChemoradiotherapy / Chemotherapy Effects / Esophagogastric Junction Cancer / Immunotherapy / Oesophagus Cancer / Targeted Therapy1
3RecruitingTreatmentDiffuse Intrinsic Pontine Gliomas (DIPG)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Injection, solutionIntravenous50 mg
Injection
Injection, solutionIntravenous50 mg/10ml
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available

Drug created at March 19, 2008 16:16 / Updated at June 19, 2021 00:26